Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone

R. A. Evans, E. Hills, C. R. Dunstan, S. Y. P. Wong

    Research output: Contribution to journalArticle

    15 Citations (Scopus)

    Abstract

    Ethane-l-hydroxy-l, l-diphosphonate (EHDP) 5 mg/kg body weight/day was administered to a patient suffering from Paget's disease of bone. After 150 days of treatment, when the plasma alkaline phosphatase was 40% of initial, he suffered a pathologic fracture of his Pagetic right patella, which was found to have osteomalacia of extreme severity. An iliac crest bone biopsy, following double tetracycline labels, also showed severe osteomalacia of Pagetic bone. Osteoclast acid phosphatase activity was reduced, as occurs in diphosphonate-treated rats. The patient's history included two previous pathologic fractures of Pagetic bone and unusual sensitivity to EHDP. It might be prudent to perform needle bone biopsy in order to exclude osteomalacia in EHDP-treated _ patients with these clinical manifestations.
    Original languageEnglish
    Pages (from-to)277-279
    Number of pages3
    JournalAustralian and New Zealand Journal of Medicine
    Volume13
    Issue number3
    DOIs
    Publication statusPublished - 1983

    Fingerprint Dive into the research topics of 'Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone'. Together they form a unique fingerprint.

  • Cite this